Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the company’s twice-a ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...